# Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

> **NCT01125449** · PHASE2 · WITHDRAWN · sponsor: **Situs Cancer Research Center**

## Conditions studied

- Sarcoma
- Adenocarcinoma
- Carcinoma
- Multiple Myeloma
- Desmoplastic Small Round Cell Tumor

## Interventions

- **DRUG:** Ascorbic acid (vitamin C)

## Key facts

- **NCT ID:** NCT01125449
- **Lead sponsor:** Situs Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche (Ireland).
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01125449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01125449, "Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01125449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*